AIMS/HYPOTHESIS: Islet amyloid in type 2 diabetes contributes to loss of beta cell mass and function. Since islets are susceptible to oxidative stress-induced toxicity, we sought to determine whether islet amyloid formation is associated with induction of oxidative stress. METHODS: Human islet amyloid polypeptide transgenic and non-transgenic mouse islets were cultured for 48 or 144 h with or without the antioxidant N-acetyl-L: -cysteine (NAC) or the amyloid inhibitor Congo Red. Amyloid deposition, reactive oxygen species (ROS) production, beta cell apoptosis, and insulin secretion, content and mRNA were measured. RESULTS: After 48 h, amyloid deposition was associated with increased ROS levels and increased beta cell apoptosis, but no change in insulin secretion, content or mRNA levels. Antioxidant treatment prevented the rise in ROS, but did not prevent amyloid formation or beta cell apoptosis. In contrast, inhibition of amyloid formation prevented the induction of oxidative stress and beta cell apoptosis. After 144 h, amyloid deposition was further increased and was associated with increased ROS levels, increased beta cell apoptosis and decreased insulin content. At this time-point, antioxidant treatment and inhibition of amyloid formation were effective in reducing ROS levels, amyloid formation and beta cell apoptosis. Inhibition of amyloid formation also increased insulin content. CONCLUSIONS/ INTERPRETATION: Islet amyloid formation induces oxidative stress, which in the short term does not mediate beta cell apoptosis, but in the longer term may feed back to further exacerbate amyloid formation and contribute to beta cell apoptosis.
AIMS/HYPOTHESIS: Islet amyloid in type 2 diabetes contributes to loss of beta cell mass and function. Since islets are susceptible to oxidative stress-induced toxicity, we sought to determine whether islet amyloid formation is associated with induction of oxidative stress. METHODS:Humanislet amyloid polypeptidetransgenic and non-transgenicmouse islets were cultured for 48 or 144 h with or without the antioxidant N-acetyl-L: -cysteine (NAC) or the amyloid inhibitor Congo Red. Amyloid deposition, reactive oxygen species (ROS) production, beta cell apoptosis, and insulin secretion, content and mRNA were measured. RESULTS: After 48 h, amyloid deposition was associated with increased ROS levels and increased beta cell apoptosis, but no change in insulin secretion, content or mRNA levels. Antioxidant treatment prevented the rise in ROS, but did not prevent amyloid formation or beta cell apoptosis. In contrast, inhibition of amyloid formation prevented the induction of oxidative stress and beta cell apoptosis. After 144 h, amyloid deposition was further increased and was associated with increased ROS levels, increased beta cell apoptosis and decreased insulin content. At this time-point, antioxidant treatment and inhibition of amyloid formation were effective in reducing ROS levels, amyloid formation and beta cell apoptosis. Inhibition of amyloid formation also increased insulin content. CONCLUSIONS/ INTERPRETATION: Islet amyloid formation induces oxidative stress, which in the short term does not mediate beta cell apoptosis, but in the longer term may feed back to further exacerbate amyloid formation and contribute to beta cell apoptosis.
Authors: J Janson; W C Soeller; P C Roche; R T Nelson; A J Torchia; D K Kreutter; P C Butler Journal: Proc Natl Acad Sci U S A Date: 1996-07-09 Impact factor: 11.205
Authors: C B Verchere; D A D'Alessio; R D Palmiter; G C Weir; S Bonner-Weir; D G Baskin; S E Kahn Journal: Proc Natl Acad Sci U S A Date: 1996-04-16 Impact factor: 11.205
Authors: S Zraika; K Aston-Mourney; D R Laybutt; M Kebede; M E Dunlop; J Proietto; S Andrikopoulos Journal: Diabetologia Date: 2006-03-29 Impact factor: 10.122
Authors: Juris J Meier; Rakez Kayed; Chia-Yu Lin; Tatyana Gurlo; Leena Haataja; Sajith Jayasinghe; Ralf Langen; Charles G Glabe; Peter C Butler Journal: Am J Physiol Endocrinol Metab Date: 2006-07-18 Impact factor: 4.310
Authors: D Schubert; C Behl; R Lesley; A Brack; R Dargusch; Y Sagara; H Kimura Journal: Proc Natl Acad Sci U S A Date: 1995-03-14 Impact factor: 11.205
Authors: Robert Kisilevsky; Walter A Szarek; John B Ancsin; Elena Elimova; Sandra Marone; Shridhar Bhat; Ali Berkin Journal: Am J Pathol Date: 2004-06 Impact factor: 4.307
Authors: Y J Park; S Lee; T J Kieffer; G L Warnock; N Safikhan; M Speck; Z Hao; M Woo; L Marzban Journal: Diabetologia Date: 2012-02-01 Impact factor: 10.122
Authors: Daniel T Meier; Leon Entrup; Andrew T Templin; Meghan F Hogan; Thanya Samarasekera; Sakeneh Zraika; Edward J Boyko; Steven E Kahn Journal: J Histochem Cytochem Date: 2015-08 Impact factor: 2.479
Authors: Daniel T Meier; Leon Entrup; Andrew T Templin; Meghan F Hogan; Mahnaz Mellati; Sakeneh Zraika; Rebecca L Hull; Steven E Kahn Journal: Diabetologia Date: 2016-09-01 Impact factor: 10.122
Authors: S Zraika; R L Hull; C B Verchere; A Clark; K J Potter; P E Fraser; D P Raleigh; S E Kahn Journal: Diabetologia Date: 2010-02-25 Impact factor: 10.122
Authors: Meghan F Hogan; Daniel T Meier; Sakeneh Zraika; Andrew T Templin; Mahnaz Mellati; Rebecca L Hull; Malcolm A Leissring; Steven E Kahn Journal: Endocrinology Date: 2016-07-12 Impact factor: 4.736